AbbVie, Inc. ABBV

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

AbbVie (NYSE: ABBV) reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress. The company selected a mid dose of zumilokibart for Phase 3 development after the study showed significant clinical improvements in patients. AbbVie joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with Valkai. The zumilokibart Phase 2 results and AbbVie’s new AI alliances matter, but investors...

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.

AbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting (Milan, Italy; September 28 – October 2). The study evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, an investigational long-acting amylin analog, in adults with a mean body m

AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Sept. 30 – Oct. 3.

AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapi

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.

The once-daily treatment reaches the U.S. market in October after improving motor-control measures across three Phase 3 studies.

AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.